Literature DB >> 4101590

Immunological responses to L-asparaginase.

R G Peterson, R E Handschumacher, M S Mitchell.   

Abstract

In a series of 40 patients treated with L-asparaginase for various neoplastic diseases, 6 patients had generalized anaphylactic reactions to L-asparaginase. Each of these reactors had antibodies detectable by passive hemagglutination, but precipitins were detectable in only one of this group of six patients. That patient had received two courses of the enzyme. 1 wk after the anaphylactic reaction, complement-fixing antibodies were present in all the patients that were studied. Specific reagin antibodies (IgE) were demonstrated in one patient by the release of histamine from his leukocytes after incubation in vitro with L-asparaginase. Binding of L-asparaginase to serum antibodies after incubation in vitro was detected by selective precipitation of the complexes with 30% ammonium sulfate or by ultracentrifugation. Total inactivation of the enzyme did not occur even at optimal proportions or at antibody excess. Passive hemagglutinating antibodies to L-asparaginase were present in all patients who had an allergic reaction at least 1 day before the reaction occurred, when that sample was available, and were absent in all patients who did not manifest clinical allergy. Titration of antibodies by passive hemagglutination may thus provide a means of predicting impending anaphylaxis in this system, particularly when coupled with a sudden decrease in circulating levels of L-asparaginase activity.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4101590      PMCID: PMC292030          DOI: 10.1172/JCI106579

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Studies on the mechanisms of hypersensitivity phenomena. XIV. Passive sensitization in vitro of human leukocytes to ragweed pollen antigen.

Authors:  D A Levy; A G Osler
Journal:  J Immunol       Date:  1966-08       Impact factor: 5.422

2.  Immunosuppressive effects of cytosine arabinoside and methotrexate in man.

Authors:  M S Mitchell; M E Wade; R C DeConti; J R Bertino; P Calabresi
Journal:  Ann Intern Med       Date:  1969-03       Impact factor: 25.391

Review 3.  Antibodies in sera of allergic individuals.

Authors:  A H Sehon; L Gyenes; F T Kisil
Journal:  Mod Trends Immunol       Date:  1967

4.  Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia.

Authors:  W C Dolowy; D Henson; J Cornet; H Sellin
Journal:  Cancer       Date:  1966-12       Impact factor: 6.860

5.  The toxicity of Escherichia coli L-asparaginase.

Authors:  P S Schein; N Rakieten; B M Gordon; R D Davis; D P Rall
Journal:  Cancer Res       Date:  1969-02       Impact factor: 12.701

6.  The antitumor activity of Escherichia coli L-asparaginase.

Authors:  J Roberts; M D Prager; N Bachynsky
Journal:  Cancer Res       Date:  1966-10       Impact factor: 12.701

7.  Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy.

Authors:  H K Miller; J S Salser; M E Balis
Journal:  Cancer Res       Date:  1969-01       Impact factor: 12.701

8.  Inhibition of leukemias in man by L-asparaginase.

Authors:  H F Oettgen; L J Old; E A Boyse; H A Campbell; F S Philips; B D Clarkson; L Tallal; R D Leeper; M K Schwartz; J H Kim
Journal:  Cancer Res       Date:  1967-12       Impact factor: 12.701

9.  L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia.

Authors:  J M Hill; J Roberts; E Loeb; A Khan; A MacLellan; R W Hill
Journal:  JAMA       Date:  1967-11-27       Impact factor: 56.272

10.  The immunoglobulin sequence. I. Arrest by 6-mercaptopurine and restitution by antibody, antigen or splenectomy.

Authors:  K Sahiar; R S Schwartz
Journal:  J Immunol       Date:  1965-08       Impact factor: 5.422

View more
  18 in total

1.  Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.

Authors:  C Liu; J D Kawedia; C Cheng; D Pei; C A Fernandez; X Cai; K R Crews; S C Kaste; J C Panetta; W P Bowman; S Jeha; J T Sandlund; W E Evans; C-H Pui; M V Relling
Journal:  Leukemia       Date:  2012-04-09       Impact factor: 11.528

2.  Development of an ELISA to detect circulating anti-asparaginase antibodies in dogs with lymphoid neoplasia treated with Escherichia coli l-asparaginase.

Authors:  J A Kidd; P Ross; A S Buntzman; P R Hess
Journal:  Vet Comp Oncol       Date:  2012-12-18       Impact factor: 2.613

3.  Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.

Authors:  S-H Chen; D Pei; W Yang; C Cheng; S Jeha; N J Cox; W E Evans; C-H Pui; M V Relling
Journal:  Clin Pharmacol Ther       Date:  2010-06-30       Impact factor: 6.875

Review 4.  Amino acid metabolism in hematologic malignancies and the era of targeted therapy.

Authors:  Yoko Tabe; Philip L Lorenzi; Marina Konopleva
Journal:  Blood       Date:  2019-08-15       Impact factor: 22.113

5.  Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells.

Authors:  R Kravtzoff; I Desbois; J P Lamagnere; J P Muh; C Valat; M Chassaigne; P Colombat; C Ropars
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

6.  Effect of premedications in a murine model of asparaginase hypersensitivity.

Authors:  Christian A Fernandez; Colton Smith; Seth E Karol; Laura B Ramsey; Chengcheng Liu; Ching-Hon Pui; Sima Jeha; William E Evans; Fred D Finkelman; Mary V Relling
Journal:  J Pharmacol Exp Ther       Date:  2015-01-08       Impact factor: 4.030

7.  Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

Authors:  Richard H Ko; Tamekia L Jones; David Radvinsky; Nathan Robison; Paul S Gaynon; Eduard H Panosyan; Ioannis A Avramis; Vassilios I Avramis; Joan Rubin; Lawrence J Ettinger; Nita L Seibel; Girish Dhall
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

8.  High-throughput asparaginase activity assay in serum of children with leukemia.

Authors:  Christian A Fernandez; Xiangjun Cai; Allie Elozory; Chengcheng Liu; J Carl Panetta; Sima Jeha; Alejandro R Molinelli; Mary V Relling
Journal:  Int J Clin Exp Med       Date:  2013-08-01

9.  Purification and properties of L-glutaminase-L-asparaginase from Pseudomonas acidovorans.

Authors:  L Davidson; D R Brear; P Wingard; J Hawkins; G B Kitto
Journal:  J Bacteriol       Date:  1977-03       Impact factor: 3.490

10.  PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.

Authors:  Young Min Kwon; Yong Tao Li; Jun F Liang; Yoon Jeong Park; Li-Chien Chang; Victor C Yang
Journal:  J Control Release       Date:  2008-06-26       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.